Barry Cukor, MD
Gastroenterology · Annapolis, MDNPI 1316115595
Payments from drug & device makers
Across 388 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Takeda Pharmaceuticals U.S.A., Inc.$612
- Johnson & Johnson$517
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$473
- Gilead$276
- Sanofi$267
- plus $2K from 31 others
What the payments were for
- Food & beverage$6,803100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 148 | $2,513 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $612 |
| Johnson & Johnson | 27 | $517 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $473 |
| Gilead | 16 | $276 |
| Sanofi | 11 | $267 |
| Pfizer | 12 | $255 |
| Merck | 13 | $218 |
| Daiichi Sankyo Inc. | 11 | $210 |
| Intercept Pharmaceuticals, Inc. | 8 | $168 |
| QOL Medical, LLC | 8 | $150 |
| Amgen | 6 | $135 |
| Redhill Biopharma Inc. | 4 | $110 |
| Nestle Healthcare Nutrition Inc. | 5 | $109 |
| Bristol Myers Squibb | 5 | $108 |
| Alnylam Pharmaceuticals Inc. | 5 | $75 |
| Endo Pharmaceuticals Inc. | 5 | $61 |
| Braintree Laboratories, Inc. | 3 | $42 |
| Organon | 3 | $42 |
| Ferring Pharmaceuticals Inc. | 3 | $41 |
| Ironwood Pharmaceuticals, Inc | 3 | $37 |
| Phathom Pharmaceuticals, Inc. | 6 | $37 |
| Lilly USA, LLC | 1 | $34 |
| Ipsen Biopharmaceuticals, Inc | 2 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $31 |
| Shionogi Inc | 2 | $29 |
| Novo Nordisk | 1 | $28 |
| Madrigal Pharmaceuticals | 1 | $28 |
| Olympus America Inc. | 1 | $22 |
| Romark Laboratories, LC | 1 | $21 |
| Fresenius Kabi USA, LLC | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
| Vivus LLC | 1 | $17 |
| Orphalan Inc | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Angiodynamics, Inc. | 1 | $12 |
How this compares
$6,803 in reported general payments places this provider in the 65th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 48 | $126,127 |
| Humira(Cf) PenAdalimumab | 12 | $80,741 |
| ZenpepLipase/Protease/Amylase | 32 | $63,812 |
| LinzessLinaclotide | 42 | $38,575 |
| Mesalamine | 46 | $28,406 |
| ViberziEluxadoline | 16 | $28,248 |
| Dexlansoprazole DrDexlansoprazole | 50 | $15,766 |
| Mesalamine ErMesalamine | 22 | $15,431 |
| AprisoMesalamine | 12 | $9,278 |
| Colestipol Hcl | 43 | $7,790 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 123 | $7,328 |
| Ursodiol | 20 | $6,305 |
| Famotidine | 221 | $3,630 |
| CholestyramineCholestyramine (With Sugar) | 40 | $3,297 |
| Pantoprazole Sodium | 193 | $2,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Viberzi | $2,513 | $192,950106 claims |
| Aimmune Therapeutics, Inc.Zenpep | $31 | $63,81232 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCApriso | $473 | $9,27812 claims |
| Braintree Laboratories, Inc.Sutab | $42 | $2,37715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Annapolis
- Michael EpsteinAnnapolis$1.4M
- Raja TaunkAnnapolis$328K
- Mark FlasarAnnapolis$168K
- Kenolisa OnwuemeBaltimore$4.5M
- Paul ThuluvathBaltimore$3.6M
- Apurva ModiRockville$3.3M
- Louis KormanChevy Chase$1.9M
- Marcia CantoBaltimore$1.6M
- Rudrajit RaiColumbia$1.4M
- Natarajan RavendhranCatonsville$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.